Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vical has reported data from a study showing that an adjuvant originally developed to boost the immune response to its DNA vaccines also boosts the immune response to a conventional influenza vaccine.
Subscribe to our email newsletter
Results from the studies suggest that the company’s patented vaccine adjuvant known as Vaxfectin has the potential to be used as a dose-sparing agent with conventional flu vaccines against seasonal or pandemic flu strains. The company is developing a Vaxfectin-formulated DNA vaccine designed to protect against emerging strains of flu virus that have the potential to cause a pandemic.
In the study Vaxfectin-formulated vaccines yielded significantly higher immune response than unformulated vaccines at the same dose.
Vical’s lead Vaxfectin-formulated, three-component DNA vaccine candidate against avian flu provided 100% protection in mice and ferrets against lethal challenges with a highly virulent H5N1 virus.
Vaxfectin formulations have demonstrated good tolerability and adjuvant activity in multiple animal models.